Summary
We report here two randomized prospective clinical trials of adjuvant treatment in the management of primary malignant melanoma of Clark’s level III, IV or V. All patients had curative resection of the primary tumor. In the first trial, 117 patients were randomized between control (surgery alone) systemic chemotherapy and intraarterial chemotherapy. Intraarterial chemotherapy consisted of DTIC 80 mg/m2 + 8 days prior to surgery. Systemic chemotherapy consisted of courses of vinblastine (6 mg/m2), thiotepa (6 mg/m2), rufocromycine (60 M£/m2)> methotrexate (15 mg/m2) on day 1, and procarbazine (30 mg/m12 x 7 days. Courses were repeated every 2 weeks x 6, then every 4 weeks x 15. Twenty-two of 55 patients relapsed in the control group versus 22 of 67 in the chemotherapy group (NS). For male patients, the difference in disease-free survival was significant (P < 0.005, log rank test), though not in women.
In the second trial, 352 patients were entered from July, 1976. Men were randomized between chemotherapy and chemoimmunotherapy. Women were randomized between surgery alone and chemoimmunotherapy. Chemotherapy was identical, except for the addition of DTIC (300 mg/m2) for each course. Immunotherapy consisted of BCG every 4 weeks and C. parvum every week. Immunotherapy seemed to be of no additional benefit.
For the Groupe de Recherches sur les Mélanomes Malins. Participating members: Aliaga, Boniche, Auclerc, Banzet, Banzet, Barrade, Biron, Belaich, Blanchet, Bonnet, Blanc, Brouaire, Cesarini, Chastang, Civatte, Cottenot, Cristo, Davan, Desprez, Curely, Dufourmentel, Edelstein, Fournier, Gauci, Goguel, Horay, Houdard, Izrael, Jacquillat, Jourdain, Lassau, Laurent, Lecam, Lepine, Maral, Najean, Noury, Duperrat, Palangier, Pecking, Picard, Pompidou, Reaux, Puissant, Real, Serrou, Texier, Trigalo, and Well
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Banzet P, Jacquillat CI, Civatte J (1978) Adjuvant chemotherapy in the management of primary malignant melanoma. Cancer 41:1240–1248
Clark WH, From L, Bernardino EA, Mihm MC. The histogenic and biological behaviour of primary human malignant melanoma of the skin.
Gutterman JO, Mavligit G, Reed R, Richman S, Mc Bride CE, Hersh EM (1975) Immunology and immunotherapy of human malignant melanoma: historic review and perspective of the future. Sem Oncol 2:155–174
Luce JK (1972) Chemotherapy of malignant melanoma. Cancer 30:1604–1605
Stehlin JS, Chark RL, Vickers WE, Monges A (1963) Perfusion for malignant melanoma of the extremities. Am J Surg 105:607–614
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Jacquillat, C., Banzet, P., Maral, J. (1982). Clinical Trials of Chemotherapy and Chemoimmunotherapy in Primary Malignant Melanoma. In: Mathé, G., Bonadonna, G., Salmon, S. (eds) Adjuvant Therapies of Cancer. Recent Results in Cancer Research, vol 80. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81685-7_40
Download citation
DOI: https://doi.org/10.1007/978-3-642-81685-7_40
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81687-1
Online ISBN: 978-3-642-81685-7
eBook Packages: Springer Book Archive